PRECISION: LUNG CANCER

Start

Tue, 13 Sep 2016, 08:00

End

Wed, 14 Sep 2016, 06:00

WebSite

http://precisionlungcancer.com/

Venue:

Exhibit

Symposia

Workshops

Organiser

Sponsor

SCOPE OF THE MEETING

Lung Cancer is the leading cause of cancer death worldwide. It is difficult to detect in its early stages, as well as understand and treat effectively.

Lung cancer R&D is experiencing rapid growth, representing an enormous opportunity for drug developers, with a 22% rise in new candidates in 2015.

The global market for Lung cancer therapeutics, currently valued at $5 billion is poised to reach $15.1 billion by 2023, expanding by a CAGR of 12%

Learning Objectives

Precision: Lung Cancer will bring together scientists and business leaders from pharma, biotech and academia, using extensive networking sessions to forge meaningful collaborations.

Discussions will revolve around translating the latest developments in the genomic and molecular understanding of the disease into new targeted therapies in the clinic.

HIGHLIGHTS

ANTIBODY DRUG CONJUGATES
IMMUNOTHERAPIES
NOVEL APPROACHES
BIOMARKERS
COMPANION DIAGNOSTICS

To Register Click Here

Day One: Tuesday September 13, 2016

7:30			REGISTRATION & COFFEE

8:15			Introduction: An Overview of the History of the Development of Targeted Therapies for Lung Cancer


Antibody Drug Conjugates for Lung Cancer


8:30		TBC

9:00		Safety and efficacy of single-agent Rovalpituzumab Tesirine, a delta-like protein 3 (DLL3)-targeted ADC in recurrent or refractory small cell lung cancer

9:30		Development of Probody™ Therapeutics and Probody Drug Conjugates (PDCs) with potential for the treatment of lung cancer

10:00		Targeted Small Molecule Drug Conjugates and Companion Imaging Agents for Personalized Lung Cancer Therapy

10:30		MORNING REFRESHMENTS & SPEED NETWORKING

11:20		TBC

11:50		Spotlight: A precise companion tool from discovery to market

12:00		Extracellular Antibody Drug Conjugates Exploiting the Proximity of Two Proteins

12:30		LUNCH & NETWORKING


Immunotherapies in Lung Cancer


1:30	Immunotherapy Combinations: An Overview


2:00	PD-L1 Biomarkers for Anti-PD-1/PD-L1 in lung cancers


2:30	Title TBC (PD-1 inhibition for lung cancer treatment)

3:00	AFTERNOON REFRESHMENTS & NETWORKING
3:30	Therapeutic strategy against tumor acidity induced immune-suppression: L-DOS47 a clinical candidate for lung cancer

4:00	Design of Multispecific Antibodies - Modulating T-Cell Functions for Redirected Cytotoxicity

4:30	Overriding immune Suppression and Increasing TILs Through Blockade of the Phosphatidylserine Signaling Pathway


Cancer Vaccines

5:00	ADXS-NEO in Lung Cancer

5:30	Title TBD: TG4010 cancer vaccine
6:00	SUMMARY & CLOSE OF DAY ONE


Day Two: Wednesday September 14, 2016


8:00	REGISTRATION & COFFEE

Immunotherapy Round Up

8:30	Opening Remarks:
	TBD

Biomarkers & Companion Diagnostics


9:00	Overview: Biomarkers and Companion Diagnostics in Anti PD-1 / Anti PDL-1 Immunotherapy
9:30	TBD

10:00	Title TBD: Overcoming resistance with combinations
10:30	PANEL DISCUSSION & SPEED NETWORKING
11:30	TBD

12:00	Path to Prospective Patient Selection in a Phase 2 Study of Seribantumab for Heregulin-Positive NSCLC

12:30	TBD

1:00	LUNCH & NETWORKING
1:30	A pilot study to assess prognostic and predictive relevance of circulating tumor DNA and circulating tumor cells in patients with advanced small cell lung cancers.

2:00	Title TBD

2:30	TARGETING CANCER STEM CELLS
	TBD

3:00	AFTERNOON REFRESHMENTS & NETWORKING
3:30	TBD

4:00	Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients

4:30	Targeting RNA splicing in Lung Cancer


5:00	TBC
	TBC
5:30	SUMMARY & CLOSE OF CONFERENCE